{"id":"ticker-lly","category":"ticker_thesis","title":"Eli Lilly (LLY) — GLP-1 Leader and Pipeline Depth","summary":"Mounjaro/Zepbound dominating obesity market; cardiovascular and Alzheimer pipeline.","trigger":{"always":false,"sectors":[],"tickers":["LLY"],"regimes":[]},"ttl_hours":336,"content":{"thesis":"LLY is the GLP-1 obesity drug market leader with Mounjaro (diabetes) and Zepbound (obesity) generating $20B+ annualized revenue. Cardiovascular benefit data for tirzepatide expanding indications. Alzheimer's pipeline (donanemab) adds optionality. Supply constraints easing through 2026.","bull_case":"GLP-1 market expands to 10%+ of adult population; oral formulation launches; cardiovascular indication drives Medicare coverage expansion","bear_case":"Reimbursement access restrictions cap addressable market; Novo Nordisk pipeline competition; muscle loss side effects cause regulatory action","key_catalysts":["Quarterly Mounjaro/Zepbound revenue vs consensus","Oral GLP-1 Phase 3 trial results","Medicare reimbursement policy decisions","Manufacturing capacity expansion milestones"],"position_guidance":"Premium valuation justified by TAM size and pipeline depth. Core healthcare holding. Add on any 10%+ pullback on non-fundamental headlines."}}